vs

Side-by-side financial comparison of ABVC BIOPHARMA, INC. (ABVC) and XCel Brands, Inc. (XELB). Click either name above to swap in a different company.

XCel Brands, Inc. is the larger business by last-quarter revenue ($1.2M vs $796.0K, roughly 1.5× ABVC BIOPHARMA, INC.). XCel Brands, Inc. runs the higher net margin — -237.8% vs -256.6%, a 18.9% gap on every dollar of revenue. On growth, ABVC BIOPHARMA, INC. posted the faster year-over-year revenue change (104.5% vs -3.4%). Over the past eight quarters, ABVC BIOPHARMA, INC.'s revenue compounded faster (1041.5% CAGR vs -26.9%).

ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.

XCel Brands, Inc. is a consumer goods and brand management firm that owns, licenses, and markets lifestyle brands spanning apparel, accessories, and home products. It operates mainly in North America, partnering with leading retail chains to distribute products to mass and mid-tier consumer segments.

ABVC vs XELB — Head-to-Head

Bigger by revenue
XELB
XELB
1.5× larger
XELB
$1.2M
$796.0K
ABVC
Growing faster (revenue YoY)
ABVC
ABVC
+107.9% gap
ABVC
104.5%
-3.4%
XELB
Higher net margin
XELB
XELB
18.9% more per $
XELB
-237.8%
-256.6%
ABVC
Faster 2-yr revenue CAGR
ABVC
ABVC
Annualised
ABVC
1041.5%
-26.9%
XELB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ABVC
ABVC
XELB
XELB
Revenue
$796.0K
$1.2M
Net Profit
$-2.0M
$-2.8M
Gross Margin
100.0%
Operating Margin
-246.8%
-166.8%
Net Margin
-256.6%
-237.8%
Revenue YoY
104.5%
-3.4%
Net Profit YoY
-417.4%
60.8%
EPS (diluted)
$-0.09
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABVC
ABVC
XELB
XELB
Q4 25
$1.2M
Q3 25
$796.0K
$1.1M
Q2 25
$1.3M
Q1 25
$1.3M
Q4 24
$2.0K
$1.2M
Q3 24
$389.3K
$1.9M
Q2 24
$117.1K
$3.0M
Q1 24
$1.2K
$2.2M
Net Profit
ABVC
ABVC
XELB
XELB
Q4 25
$-2.8M
Q3 25
$-2.0M
$-7.9M
Q2 25
$-4.0M
Q1 25
$-2.8M
Q4 24
$-7.1M
Q3 24
$-394.8K
$-9.2M
Q2 24
$-942.3K
$195.0K
Q1 24
$-2.8M
$-6.3M
Gross Margin
ABVC
ABVC
XELB
XELB
Q4 25
Q3 25
100.0%
100.0%
Q2 25
100.0%
Q1 25
Q4 24
100.0%
100.0%
Q3 24
99.9%
78.7%
Q2 24
99.8%
98.7%
Q1 24
77.0%
100.0%
Operating Margin
ABVC
ABVC
XELB
XELB
Q4 25
-166.8%
Q3 25
-246.8%
-665.7%
Q2 25
-125.2%
Q1 25
-164.2%
Q4 24
-532.9%
Q3 24
-77.7%
-474.8%
Q2 24
-734.2%
10.4%
Q1 24
-235539.8%
-283.7%
Net Margin
ABVC
ABVC
XELB
XELB
Q4 25
-237.8%
Q3 25
-256.6%
-706.5%
Q2 25
-301.9%
Q1 25
-210.0%
Q4 24
-585.9%
Q3 24
-101.4%
-481.9%
Q2 24
-804.4%
6.6%
Q1 24
-235203.2%
-288.2%
EPS (diluted)
ABVC
ABVC
XELB
XELB
Q4 25
$-0.22
Q3 25
$-0.09
$-2.02
Q2 25
$-1.66
Q1 25
$-1.18
Q4 24
$-2.91
Q3 24
$-0.03
$-3.92
Q2 24
$-0.08
$0.08
Q1 24
$-0.29
$-3.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABVC
ABVC
XELB
XELB
Cash + ST InvestmentsLiquidity on hand
$257.2K
$1.1M
Total DebtLower is stronger
$12.7M
Stockholders' EquityBook value
$12.1M
$18.0M
Total Assets
$21.2M
$38.9M
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABVC
ABVC
XELB
XELB
Q4 25
$1.1M
Q3 25
$257.2K
$1.5M
Q2 25
$970.0K
Q1 25
$298.0K
Q4 24
$313.1K
$1.3M
Q3 24
$208.2K
$242.0K
Q2 24
$200.0K
$924.0K
Q1 24
$106.4K
$1.6M
Total Debt
ABVC
ABVC
XELB
XELB
Q4 25
$12.7M
Q3 25
$12.5M
Q2 25
$12.3M
Q1 25
$8.7M
Q4 24
$6.6M
Q3 24
$4.3M
Q2 24
$4.5M
Q1 24
$4.7M
Stockholders' Equity
ABVC
ABVC
XELB
XELB
Q4 25
$18.0M
Q3 25
$12.1M
$18.7M
Q2 25
$24.5M
Q1 25
$27.7M
Q4 24
$1.2M
$30.4M
Q3 24
$1.6M
$36.9M
Q2 24
$1.8M
$46.0M
Q1 24
$1.7M
$45.8M
Total Assets
ABVC
ABVC
XELB
XELB
Q4 25
$38.9M
Q3 25
$21.2M
$40.5M
Q2 25
$47.2M
Q1 25
$52.5M
Q4 24
$7.5M
$53.8M
Q3 24
$7.8M
$54.0M
Q2 24
$8.0M
$63.2M
Q1 24
$8.0M
$66.8M
Debt / Equity
ABVC
ABVC
XELB
XELB
Q4 25
0.71×
Q3 25
0.67×
Q2 25
0.50×
Q1 25
0.31×
Q4 24
0.22×
Q3 24
0.12×
Q2 24
0.10×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABVC
ABVC
XELB
XELB
Operating Cash FlowLast quarter
$-964.7K
$-7.0M
Free Cash FlowOCF − Capex
$-7.0M
FCF MarginFCF / Revenue
-602.1%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABVC
ABVC
XELB
XELB
Q4 25
$-7.0M
Q3 25
$-964.7K
$-1.4M
Q2 25
$-2.4M
Q1 25
$-1.4M
Q4 24
$-1.8M
$-4.7M
Q3 24
$60.2K
$-424.0K
Q2 24
$-211.4K
$-274.0K
Q1 24
$-955.8K
$-2.6M
Free Cash Flow
ABVC
ABVC
XELB
XELB
Q4 25
$-7.0M
Q3 25
Q2 25
$-2.4M
Q1 25
$-1.4M
Q4 24
$-4.8M
Q3 24
$-432.0K
Q2 24
Q1 24
FCF Margin
ABVC
ABVC
XELB
XELB
Q4 25
-602.1%
Q3 25
Q2 25
-179.3%
Q1 25
-108.7%
Q4 24
-399.3%
Q3 24
-22.6%
Q2 24
Q1 24
Capex Intensity
ABVC
ABVC
XELB
XELB
Q4 25
0.9%
Q3 25
0.0%
Q2 25
0.3%
Q1 25
1.1%
Q4 24
9.3%
Q3 24
0.4%
Q2 24
Q1 24
Cash Conversion
ABVC
ABVC
XELB
XELB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons